Syros Pharmaceuticals, Inc. (SYRS) Institutional Ownership

Based on Q1 2026 13F filings, institutional ownership of Syros Pharmaceuticals, Inc. stands at 200.0%, held across 1 reporting institutions.

Marex Group plc is the largest reported institutional holder of SYRS, with approximately 12,700 shares worth $0.00B as of Q1 2026.

No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of SYRS.

Our composite Smart Money Score for SYRS is 62 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

1 institutions opened new positions in SYRS during Q1 2026, while 0 fully exited. 0 added to existing positions and 0 trimmed.

SYRS institutional ownership rose by 199.10 percentage points quarter-over-quarter, with a net change of +1 holders.

The top 10 institutions account for 100.0% of all reported 13F value in SYRS, and the top 25 account for 100.0%.

All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.